Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase EARLY_PHASE1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Genitourinary 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 210Cyclophosphamide 122Nivolumab 109Carboplatin 92fludarabine 81Gemcitabine 77Specimen Handling 74Bevacizumab 72venetoclax 70Injections 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 56Cisplatin 53Ipilimumab 50Temozolomide 45Docetaxel 42Azacitidine 42Pemetrexed 41Lenalidomide 41Oxaliplatin 40Rituximab 39Radiotherapy 39Fluorouracil 39Cetuximab 37durvalumab 36Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Immunoconjugates × 1 year × Clear all
NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

MBrace Therapeutics

Phase 1/2 Recruiting
130 enrolled
Tumor-Agnostic

Neoplasms

NCT06797999 2026-01-28

ADCElerate1

Adcendo ApS

Phase 1/2 Recruiting
270 enrolled
Sarcoma

Sarcoma

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡